A phase 1/2 trial of MHB048C for Injection in prostate cancer, run by Minghui Pharmaceutical (Hangzhou) Ltd, now recruiting.
A Study of MHB048C in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07192120 by Minghui Pharmaceutical (Hangzhou) Ltd, with 200 participants planned, started 2026-01-16 and due to reach its primary completion in 2029-10. Interventions recorded: MHB048C for Injection.
Shares Minghui Pharmaceutical and the tag pipeline.
Shares Minghui Pharmaceutical and the tag pipeline.
Shares Minghui Pharmaceutical and the tag pipeline.
Shares Minghui Pharmaceutical and the tag pipeline.
Shares Minghui Pharmaceutical and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.